Cardiodynamics (Nasdaq: CDIC - http://www.cardiodynamics.com)is a small, yet undiscovered company in San Diego which manufactures cardiac monitoring devices.
Their patented BioZ system uses noninvasive technology to monitor crucial hemodynamic parameters of the heart. This system is poised to replace the current monitoring process, which relies on invasive catheters and which can lead to complications such as infections and sometimes even death. The noninvasive BioZ system eliminates such patient risks and as an added bonus also reduces patient cost significantly. Their medical advisory board includes some of the most highly respected cardiologists in the US.
Cardiodynamics is currently in the process of introducing and selling this novel system to doctors in the US. Sales are expected to be very strong and will most probably remain so for the next several decades because:
Heart disease is on the rise in industrialized countries.
The proportion of elderly citizens (potential heart disease patients)in industrialized nations is on the rise as well.
The BioZ system eliminates all risk for the patient in hemodynamic heart monitoring.
The BioZ system is highly cost effective compared to the invasive catheter system and will thus be embraced by hospitals and HMOs.
In my opinion Cardiodynamics is in a position to capture a significant share of the $259 billion spent annualy in the US on cardiovascular diseases and as a result will see a sharp appreciation of its shareprice.
Don't know why you're cluttering the ABT board with a plug on Cardiodynamics, but I would add a word of caution to those doing their research. Check out what the potential competition is for this approach. I understand that Mallinckrodt has a diagnostic imaging agent in clinical trials that is also a non-invasive alternative to cardiac catheterization, and doesn't require hospitals and clinics to buy new capital equipment.
P.S. I had a heart attack a few months ago and had to undergo cardiac catheterization twice. Getting the bleeding stopped after the procedure is the nasty part -- I would have loved to have had either new approach available.